Covid‐19 and dengue: Double punches for dengue‐endemic countries in Asia

DOI Web Site Web Site 被引用文献1件
  • Harapan Harapan
    Medical Research Unit, School of Medicine Universitas Syiah Kuala Banda Aceh Indonesia
  • Mirza Ryan
    Medical Research Unit, School of Medicine Universitas Syiah Kuala Banda Aceh Indonesia
  • Benediktus Yohan
    Eijkman Institute for Molecular Biology Jakarta Indonesia
  • Rufika Shari Abidin
    Faculty of Medicine Hasanuddin University Makassar Indonesia
  • Firzan Nainu
    Faculty of Pharmacy Hasanuddin University Makassar Indonesia
  • Ahmed Rakib
    Department of Pharmacy, Faculty of Biological Sciences University of Chittagong Chittagong Bangladesh
  • Israt Jahan
    Department of Pharmacy International Islamic University Chittagong Chittagong Bangladesh
  • Talha Bin Emran
    Department of Pharmacy BGC Trust University Bangladesh Chittagong Bangladesh
  • Irfan Ullah
    Kabir Medical College Gandhara University Peshawar Pakistan
  • Kritu Panta
    School of Biomedical Sciences The University of Western Australia Crawley Australia
  • Kuldeep Dhama
    Division of Pathology ICAR‐Indian Veterinary Research Institute Bareilly India
  • R. Tedjo Sasmono
    Eijkman Institute for Molecular Biology Jakarta Indonesia

説明

<jats:title>Summary</jats:title><jats:p>The coronavirus disease 2019 (Covid‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is an international public health crisis with devastating effects. In particular, this pandemic has further exacerbated the burden in tropical and subtropical regions of the world, where dengue fever, caused by dengue virus (DENV), is already endemic to the population. The similar clinical manifestations shared by Covid‐19 and dengue fever have raised concerns, especially in dengue‐endemic countries with limited resources, leading to diagnostic challenges. In addition, cross‐reactivity of the immune responses in these infections is an emerging concern, as pre‐existing DENV‐antibodies might potentially affect Covid‐19 through antibody‐dependent enhancement. In this review article, we aimed to raise the issue of Covid‐19 and dengue fever misdiagnosis, not only in a clinical setting but also with regards to cross‐reactivity between SARS‐CoV‐2 and DENV antibodies. We also have discussed the potential consequences of overlapping immunological cascades between dengue and Covid‐19 on disease severity and vaccine development.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ